INmune Bio, Inc. (INMB)

INmune Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	26	35.85	52.15	74.81	21.97	7
Cash & Cash Equivalents	26	35.85	52.15	74.81	21.97	7
Cash Growth	-49.02%	-31.26%	-30.29%	240.56%	214.02%	3656.91%
Other Current Assets	3.82	4.09	12.52	7.8	2.02	0.77
Total Current Assets	29.82	39.94	64.68	82.61	23.99	7.76
Property, Plant & Equipment	0.39	0.41	0.51	0.73	0.16	0.19
Goodwill and Intangibles	16.51	16.51	16.51	16.51	16.51	16.51
Other Long-Term Assets	0.11	0.13	0.1	0.1	0	0
Total Long-Term Assets	17.01	17.06	17.12	17.34	16.67	16.71
Total Assets	46.83	57	81.8	99.95	40.66	24.47
Accounts Payable	9.35	7.94	5.22	3.81	1.55	0.69
Current Debt	7.58	10.04	5.09	0.07	0.03	0.01
Other Current Liabilities	0.52	0.49	0.62	0.47	0.19	0
Total Current Liabilities	17.45	18.47	10.92	4.36	1.78	0.7
Long-Term Debt	0.36	0.4	10.22	15.16	0.13	0.16
Other Long-Term Liabilities	0	0	0.55	0.2	0	0
Total Long-Term Liabilities	0.36	0.4	10.77	15.36	0.13	0.16
Total Liabilities	17.81	18.86	21.69	19.72	1.9	0.86
Total Debt	7.94	10.44	15.31	15.23	0.16	0.17
Debt Growth	-48.33%	-31.83%	0.50%	9421.25%	-5.02%	-
Retained Earnings	-132.05	-121.02	-91.01	-63.72	-33.38	-21.28
Comprehensive Income	-0.67	-0.8	-0.7	0	0.01	-0.01
Shareholders' Equity	28.22	37.34	60.1	80.23	38.75	23.61
Net Cash / Debt	18.06	25.41	36.84	59.58	21.81	6.83
Net Cash / Debt Growth	-49.31%	-31.03%	-38.16%	173.20%	219.42%	3566.45%
Net Cash Per Share	1.00	1.41	2.06	3.69	1.82	0.66
Working Capital	12.37	21.48	53.76	78.25	22.21	7.06
Book Value Per Share	1.57	2.08	3.35	4.97	3.23	2.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).